Hyperimmune bovine colostrum as a novel therapy to combat clostridium difficile infection

Journal of Infectious Diseases

Volumn 211, Issue 8, 2015, Pages 1334-1341

  Sponseller, Jerlyn K ^a   Steele, Jennifer A ^a   Schmidt, Diane J ^a   Kim, Hyeun Bum ^a,b   Beamer, Gillian ^a   Sun, Xingmin ^a   Tzipori, Saul ^a  

^a TUFTS UNIVERSITY   (United States)

^b Dankook University   (South Korea)

Author keywords

Clostridium difficile; hyperimmune bovine colostrum; immunotherapeutic; intestinal microbiota; intestinal microflora

Indexed keywords

HYPERIMMUNE BOVINE COLOSTRUM; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 8; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; IMMUNOLOGIC FACTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLON ULCER; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FREEZE DRYING; HUMAN; INTESTINE FLORA; INTESTINE MUCOSA; MALE; NONHUMAN; NORMAL HUMAN; PIGLET; PRIORITY JOURNAL; ANIMAL; BOVINE; CLOSTRIDIUM INFECTIONS; COLOSTRUM; ENTEROPATHY; IMMUNOLOGY; INTESTINE; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; PIG; PREGNANCY;

AGED; ANIMALS; ANTI-BACTERIAL AGENTS; CATTLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS; COLOSTRUM; DIARRHEA; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTESTINAL DISEASES; INTESTINES; MALE; MIDDLE AGED; PREGNANCY; SWINE;

EID: 84926665081     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu605     Document Type: Conference Paper

References (50)

1. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5:549-57.
2. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346:334-9.
3. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58:403-10.
4. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257-62.
5. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38:2386-8.
6. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 2005; 54:101-11.
7. Mattila E, Anttila VJ, Broas M, et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis 2008; 40:702-8.
8. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
9. Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 2012; 55:216-23.
10. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14:929-31.
11. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 13:1417-9.
12. Marsh JW, Arora R, Schlackman JL, Shutt KA, Curry SR, Harrison LH. Association of relapse of Clostridium difficile disease with BI/NAP1/027. J Clin Microbiol 2012; 50:4078-82.
13. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-72.
14. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-7.
15. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173:1037-42.
16. Steele J, Sponseller J, Schmidt D, Cohen O, Tzipori S. Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile. Hum Vaccin Immunother 2013; 9:1565-8.
17. Steele J, Mukherjee J, Parry N, Tzipori S. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clos-tridium difficile disease. J Infect Dis 2013; 207:323-30.
18. Kelly CP, Pothoulakis C, Vavva F, et al. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and entero-toxicity of C. difficile toxins. Antimicrob Agents Chemother 1996; 40:373-9.
19. Naaber P, Lehto E, Salminen S, Mikelsaar M. Inhibition of adhesion of Clostridium difficile to Caco-2 cells. FEMS Immunol Med Microbiol 1996; 14:205-9.
20. Lyerly DM, Bostwick EF, Binion SB, Wilkins TD. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 1991; 59:2215-8.
21. Warny M, Fatimi A, Bostwick EF, et al. Bovine immunoglobulin con-centrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 1999; 44:212-7.
22. Kelly CP, Chetham S, Keates S, et al. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother 1997; 41:236-41.
23. Numan SC, Veldkamp P, Kuijper EJ, van den Berg RJ, van Dissel JT. Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007; 56:888-9.
24. Wang H, Sun X, Zhang Y, et al. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun 2012; 80:2678-88.
25. Amuguni H, Lee S, Kerstein K, et al. Sublingual immunization with an engineered Bacillus subtilis strain expressing tetanus toxin fragment C induces systemic and mucosal immune responses in piglets. Microbes Infect 2012; 14:447-56.
26. Steele J, Feng H, Parry N, Tzipori S. Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis 2010; 201:428-34.
27. Barbut F, Kajzer C, Planas N, Petit JC. Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 1993; 31:963-7.
28. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:761-7.
29. Zhang Q, Widmer G, Tzipori S. A pig model of the human gastrointestinal tract. Gut Microbes 2013; 4:193-200.
30. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 2011; 27:2194-200.
31. Cole JR, Wang Q, Cardenas E, et al. The Ribosomal Database Project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res 2009; 37:D141-5.
32. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010; 7:335-6.
33. Shing CM, Peake JM, Suzuki K, Jenkins DG, Coombes JS. Bovine colostrum modulates cytokine production in human peripheral blood mononuclear cells stimulated with lipopolysaccharide and phytohe-magglutinin. J Interferon Cytokine Res 2009; 29:37-44.
34. Marchbank T, Davison G, Oakes JR, et al. The nutriceutical bovine colostrum truncates the increase in gut permeability caused by heavy exercise in athletes. Am J Physiol Gastrointest Liver Physiol 2011; 300:G477-84.
35. Khan Z, Macdonald C, Wicks AC, et al. Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study. Aliment Pharmacol Ther 2002; 16:1917-22.
36. Greenberg PD, Cello JP. Treatment of severe diarrhea caused by Cryp-tosporidium parvum with oral bovine immunoglobulin concentrate in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:348-54.
37. Panahi Y, Falahi G, Falahpour M, et al. Bovine colostrum in the management of nonorganic failure to thrive: a randomized clinical trial. J Pediatr Gastroenterol Nutr 2010; 50:551-4.
38. Kaducu FO, Okia SA, Upenytho G, Elfstrand L, Floren CH. Effect of bovine colostrum-based food supplement in the treatment of HIV-associated diarrhea in Northern Uganda: a randomized controlled trial. Indian J Gastroenterol 2011; 30:270-6.
39. Mitra AK, Mahalanabis D, Ashraf H, Unicomb L, Eeckels R, Tzipori S. Hyperimmune cow colostrum reduces diarrhoea due to rotavirus: a double-blind, controlled clinical trial. Acta Paediatr 1995; 84:996-1001.
40. Sarker SA, Casswall TH, Mahalanabis D, et al. Successful treatment of rotavirus diarrhea in children with immunoglobulin from immunized bovine colostrum. Pediatr Infect Dis J 1998; 17:1149-54.
41. Playford RJ, MacDonald CE, Calnan DP, et al. Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability. Clin Sci (Lond) 2001; 100:627-33.
42. Otto W, Najnigier B, Stelmasiak T, Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers. Scand J Gastroenterol 2011; 46:862-8.
43. Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg 1992; 47:276-83.
44. Tzipori S, Roberton D, Chapman C. Remission of diarrhoea due to cryptosporidiosis in an immunodeficient child treated with hyper-immune bovine colostrum. Br Med J (Clin Res Ed) 1986; 293: 1276-7.
45. Tzipori S, Roberton D, Cooper DA, White L. Chronic cryptosporidial diarrhoea and hyperimmune cow colostrum. Lancet 1987; 2:344-5.
46. Klobasa F, Goel MC, Werhahn E. Comparison of freezing and lyophi-lizing for preservation of colostrum as a source of immunoglobulins for calves. J Anim Sci 1998; 76:923-6.
47. Hurley WL, Theil PK. Perspectives on immunoglobulins in colostrum and milk. Nutrients 2011; 3:442-74.
48. Stelwagen K, Carpenter E, Haigh B, Hodgkinson A, Wheeler TT. Immune components of bovine colostrum and milk. J Anim Sci 2009; 87:3-9.
49. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010; 74:309-18.
50. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55(suppl 2):S88-92.